用于引起急性肠胃炎的病毒和细菌病原体的疫苗：第二部分：志贺氏菌、沙门氏菌、产肠毒素大肠杆菌（ETEC）、肠出血性大肠杆菌（EHEC）和空肠弯曲菌的疫苗。
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.
作者信息
O'Ryan Miguel, Vidal Roberto, del Canto Felipe, Carlos Salazar Juan, Montero David
机构信息
a Microbiology and Mycology Program; Institute of Biomedical Sciences; Faculty of Medicine; Universidad de Chile; Santiago, Chile.
出版信息
Hum Vaccin Immunother. 2015;11(3):601-19. doi: 10.1080/21645515.2015.1011578.
Abstract
In Part II we discuss the following bacterial pathogens: Shigella, Salmonella (non-typhoidal), diarrheogenic E. coli (enterotoxigenic and enterohemorragic) and Campylobacter jejuni. In contrast to the enteric viruses and Vibrio cholerae discussed in Part I of this series, for the bacterial pathogens described here there is only one licensed vaccine, developed primarily for Vibrio cholerae and which provides moderate protection against enterotoxigenic E. coli (ETEC) (Dukoral(®)), as well as a few additional candidates in advanced stages of development for ETEC and one candidate for Shigella spp. Numerous vaccine candidates in earlier stages of development are discussed.
摘要
在第二部分中，我们将讨论以下几种细菌病原体：志贺氏菌、沙门氏菌（非伤寒型）、致泻性大肠杆菌（产肠毒素型和肠出血型）以及空肠弯曲菌。与本系列第一部分中讨论的肠道病毒和霍乱弧菌不同，对于此处描述的细菌病原体，只有一种已获许可的疫苗，该疫苗主要是针对霍乱弧菌研发的，对产肠毒素型大肠杆菌（ETEC）有一定的保护作用（杜科拉尔（Dukoral(®)）），此外还有一些处于研发后期的针对ETEC的候选疫苗以及一种针对志贺氏菌属的候选疫苗。本文还讨论了许多处于研发早期阶段的候选疫苗。
相似文献
1
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.
Hum Vaccin Immunother. 2015;11(3):601-19. doi: 10.1080/21645515.2015.1011578.
2
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae.
Hum Vaccin Immunother. 2015;11(3):584-600. doi: 10.1080/21645515.2015.1011019.
3
A review of the current status of enteric vaccines.
P N G Med J. 1995 Dec;38(4):325-31.
4
Future vaccines against enteric pathogens.
Infect Dis Clin North Am. 1990 Mar;4(1):105-21.
5
From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development.
Indian J Med Res. 2011 Feb;133(2):188-96.
6
Immunization with a Double-Mutant (R192G/L211A) of the Heat-Labile Enterotoxin of Escherichia coli Offers Partial Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model.
PLoS One. 2015 Nov 5;10(11):e0142090. doi: 10.1371/journal.pone.0142090. eCollection 2015.
7
Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Vaccine. 2007 Dec 12;25(51):8574-84. doi: 10.1016/j.vaccine.2007.09.074. Epub 2007 Oct 26.
8
Vaccines against gastroenteritis, current progress and challenges.
Gut Microbes. 2020 Nov 1;11(6):1486-1517. doi: 10.1080/19490976.2020.1770666. Epub 2020 Jun 18.
9
Global burden of diarrheal diseases among children in developing countries: Incidence, etiology, and insights from new molecular diagnostic techniques.
Vaccine. 2017 Dec 14;35(49 Pt A):6783-6789. doi: 10.1016/j.vaccine.2017.07.036. Epub 2017 Jul 29.
10
Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine.
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8794-9. doi: 10.1073/pnas.0914121107. Epub 2010 Apr 26.
引用本文的文献
1
Subtractive proteomics and reverse-vaccinology approaches for novel drug targets and designing a chimeric vaccine against strain RJX1120.
Front Immunol. 2025 Apr 14;16:1555741. doi: 10.3389/fimmu.2025.1555741. eCollection 2025.
2
Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms.
Biosaf Health. 2022 Dec 2;5(1):45-61. doi: 10.1016/j.bsheal.2022.11.002. eCollection 2023 Feb.
3
Multidrug-resistant ESBL in urban surface waters and public health implications: A Case Study from Goranchatbari, Dhaka.
Heliyon. 2025 Jan 23;11(3):e42219. doi: 10.1016/j.heliyon.2025.e42219. eCollection 2025 Feb 15.
4
Validation of a Human Challenge Model Using an LT-Expressing Enterotoxigenic Strain (LSN03-016011) and Characterization of Potential Amelioration of Disease by an Investigational Oral Vaccine Candidate (VLA1701).
Microorganisms. 2024 Apr 3;12(4):727. doi: 10.3390/microorganisms12040727.
5
The Planetary Child Health & Enterics Observatory (Plan-EO): A protocol for an interdisciplinary research initiative and web-based dashboard for mapping enteric infectious diseases and their risk factors and interventions in LMICs.
PLoS One. 2024 Feb 27;19(2):e0297775. doi: 10.1371/journal.pone.0297775. eCollection 2024.
6
A chimeric protein-based vaccine elicits a strong IgG antibody response and confers partial protection against Shiga toxin-producing in mice.
Front Immunol. 2023 Jul 27;14:1186368. doi: 10.3389/fimmu.2023.1186368. eCollection 2023.
7
Safety and Immunogenicity of a Chimeric Subunit Vaccine against Shiga Toxin-Producing in Pregnant Cows.
Int J Mol Sci. 2023 Feb 1;24(3):2771. doi: 10.3390/ijms24032771.
8
Protective Immunity Against Enterotoxigenic Escherichia coli by Oral Vaccination of Engineered Lactococcus lactis.
Curr Microbiol. 2021 Sep;78(9):3464-3473. doi: 10.1007/s00284-021-02601-x. Epub 2021 Jul 15.
9
Long-read-sequenced reference genomes of the seven major lineages of enterotoxigenic Escherichia coli (ETEC) circulating in modern time.
Sci Rep. 2021 Apr 29;11(1):9256. doi: 10.1038/s41598-021-88316-2.
10
Deciphering Additional Roles for the EF-Tu, l-Asparaginase II and OmpT Proteins of Shiga Toxin-Producing .
Microorganisms. 2020 Aug 4;8(8):1184. doi: 10.3390/microorganisms8081184.
本文引用的文献
1
Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines.
Vaccine. 2014 Oct 21;32(46):6122-9. doi: 10.1016/j.vaccine.2014.08.056. Epub 2014 Sep 3.
2
Immunoproteomic analysis to identify Shiga toxin-producing Escherichia coli outer membrane proteins expressed during human infection.
Infect Immun. 2014 Nov;82(11):4767-77. doi: 10.1128/IAI.02030-14. Epub 2014 Aug 25.
3
Passive immunity with multi-serotype heat-killed Shigellae in neonatal mice.
Microbiol Immunol. 2014 Aug;58(8):463-6. doi: 10.1111/1348-0421.12164.
4
Pathobiology of salmonella, intestinal microbiota, and the host innate immune response.
Front Immunol. 2014 May 26;5:252. doi: 10.3389/fimmu.2014.00252. eCollection 2014.
5
Characterization of adaptive immune responses induced by a new genetically inactivated Salmonella Enteritidis vaccine.
Comp Immunol Microbiol Infect Dis. 2014 May;37(3):159-67. doi: 10.1016/j.cimid.2014.05.001. Epub 2014 May 17.
6
Vaccines against invasive Salmonella disease: current status and future directions.
Hum Vaccin Immunother. 2014;10(6):1478-93. doi: 10.4161/hv.29054. Epub 2014 May 7.
7
Changing patterns and widening of antibiotic resistance in Shigella spp. over a decade (2000-2011), Andaman Islands, India.
Epidemiol Infect. 2015 Feb;143(3):470-7. doi: 10.1017/S0950268814000958. Epub 2014 Apr 24.
8
Bacterial outer membrane vesicles and vaccine applications.
Front Immunol. 2014 Mar 24;5:121. doi: 10.3389/fimmu.2014.00121. eCollection 2014.
9
Variable efficacy of a vaccine and direct-fed microbial for controlling Escherichia coli O157:H7 in feces and on hides of feedlot cattle.
Foodborne Pathog Dis. 2014 May;11(5):379-87. doi: 10.1089/fpd.2013.1693. Epub 2014 Mar 27.
10
Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies.
Infect Immun. 2014 May;82(5):2027-36. doi: 10.1128/IAI.01665-13. Epub 2014 Mar 4.
Zotero 插件